YESCARTA
NDC 71287-119 · Kite Pharma, Inc.
Generic nameaxicabtagene ciloleucel
Dosage formSUSPENSION
RouteINTRAVENOUS
Active ingredient(s)AXICABTAGENE CILOLEUCEL
Strength2000000 1/68mL
Pharmacologic classCD19 Receptor Interactions [MoA], CD19-directed Chimeric Antigen Receptor [EPC], CD19-specific Chimeric Antigen Receptor [CS], Genetically-modified Autologous T Cells [EPC], Increased T Lymphocyte Activation [PE], T Lymphocytes, Cultured, Autologous, Genetically-modified [EXT]
Marketing categoryBLA
Packages
71287-119-02 — 1 BAG in 1 PACKAGE (71287-119-02) / 68 mL in 1 BAG (71287-119-01)
Billed under HCPCS
Q2041 — Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Medicare Part B payment limit (ASP + 6%): $562500.89